Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
Zou Z, Gu Y, Liang L, Hao X, Fan C, Xin T, Zhao S, Liu Z, Guo Y, Ma K, Li H, Zhang C, Shan L, Zhang Y, Dong G, Peng Y, Shen F, Song X, Christopoulos P, van der Wekken AJ, Okuda K, Ekman S, Xing P, Li J.
Zou Z, et al. Among authors: liang l.
Transl Lung Cancer Res. 2022 Dec;11(12):2495-2506. doi: 10.21037/tlcr-22-803.
Transl Lung Cancer Res. 2022.
PMID: 36636411
Free PMC article.